and JERUSALEM, Aug. 12, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported its second quarter 2026 financial results and provided an operational update. Recent Financial and Operational HighlightsRevenue in the second quarter of 2026 increased 35% to $17.1 million, compared with $12.6 million in the second quarter of 2025. Net income for the second quarter of 2026 increased 34% to $2.7 million, compared with $2.0 million for the prior year period. As of June 30, 2026, cash and cash equivalents and restricted cash totaled $62.4 million, an increase of approximately 6% compared with March 31, 2026. In addition to operating income (loss) and net income (loss), we use Adjusted EBITDA as a measure of operational efficiency.